Journal of Stem Cells & Regenerative Medicine最新文献

{"title":"Stress Management: COVID-19 - Psychological and Spiritual Context.","authors":"Francis P Xavier","doi":"10.46582/jsrm.1602014","DOIUrl":"https://doi.org/10.46582/jsrm.1602014","url":null,"abstract":"Any crisis (personal or collective) brings along an in-built stress. It cripples people from living a normal life; sometimes it leads people to the extreme condition of permanent damage. The COVID-19 situation has brought in unexpected misery - victimizing millions of people. It has been an equalizer as both the rich and the poor have been affected; both the affluent and the developing countries have become a prey to the pandemic. For nearly one year the world is wondering which way to turn for comfort or solution, as the fear of the second and third waves looms over. Science has not given the timely preventive medication; world leaders are not able to lead the people with effective insight; financial system is on the brink of collapse; and even the faith of people seems to become a question mark. But any problem should have a solution, with often multiple aspects of solutions. Apart from medicine, one could become strengthened to face the situation. Starting with the analysis of the cause and the effect of Coronavirus Pandemic, this talk explores the intellectual and emotional aspects of the situation with the focus on the psychological and spiritual solutions to face the crisis; how to get reconciled with the reality; and how to thrive in his situation. The ultimate goal is to come out of the crisis with a spirit of creativity. If the pandemic is a period of cocoon, the butterfly-joy would be the hope to come out soon. And we need to stay energized to realize the fullness of life with peace of the mind, health of the body, and joy of the heart. Practical suggestions are put forward to face, encounter, and overcome the situation.","PeriodicalId":17155,"journal":{"name":"Journal of Stem Cells & Regenerative Medicine","volume":"16 2","pages":"92"},"PeriodicalIF":2.7,"publicationDate":"2020-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772812/pdf/jsrm_16_92.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38795718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Achatina fulica mucous improves cell viability and increases collagen deposition in UVB-irradiated human fibroblast culture.","authors":"Ch Tri Nuryana,&nbsp;Sofia Mubarika Haryana,&nbsp;Yohanes Widodo Wirohadidjojo,&nbsp;Nur Arfian","doi":"10.46582/jsrm.1601005","DOIUrl":"https://doi.org/10.46582/jsrm.1601005","url":null,"abstract":"<p><p><b>Introduction:</b> Ultraviolet radiation induces skin photoaging by increasing matrix metalloproteinase-1 (MMP-1). MMP-1 degrades type I and III collagen that comprise the dermal connective tissue. <i>Achatina fulica</i> mucous (AFM) is a natural remedy that has protective effects on fibroblasts and collagen. <b>Objective:</b> To investigate the effects of AFM on cell viability and collagen deposition in UVB-irradiated human fibroblast culture. <b>Methods:</b> The mucous was extracted from 50 <i>Achatina fulica</i> snails that were stimulated by a 5-10 Volt electricity shock for 30-60 seconds and converted into powder by the freeze-drying process. The human dermal fibroblast culture was divided into six groups: group 1 were normal fibroblasts without UVB irradiation as normal control, groups 2-5 consisted of 100 mJ/cm² UVB-irradiated fibroblasts. Group 2 had no treatment as negative control, group 3 was treated by PRP 10% as positive control group and groups 4-6 were treated by various concentrations of AFM (3.9; 15.625 and 62.5 μg/mL). At the end of the experiment, the proliferation was assessed with MTT assay, furthermore collagen deposition was measured by Sirius red assay. Real Time-PCR (RT-PCR) was performed to quantify Coll I, Coll III and MMP-1 mRNA expression, then to measured COL 1/COL III ratio. <b>Results:</b> UVB induced significant lower viability, upregulated MMP-1 and downregulated COL I and COL III mRNA expressions. Meanwhile AFM treated groups demonstrated higher cell viability with downregulation of MMP-1 and upregulation of COL I and COL III mRNA expressions. The ratio of COL I/ III expression was significantly (<i>p</i><0.05) lower in the AFM treated groups compared to the UVB group. Among AFM treated groups, administration of 62.5 μg/mL AFM represented the best result. <b>Conclusion:</b> AFM may ameliorate viability of UVB-irradiated human fibroblast culture which associates with downregulating MMP-1, upregulating COL I and Col III, and reducing COL I/III ratio.</p>","PeriodicalId":17155,"journal":{"name":"Journal of Stem Cells & Regenerative Medicine","volume":"16 1","pages":"26-31"},"PeriodicalIF":2.7,"publicationDate":"2020-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7282269/pdf/jsrm_16_26.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38042446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of AD-MSCs injections for the treatment of knee osteoarthritis: Analysis of the current literature.","authors":"Angelo V Vasiliadis,&nbsp;Nikiforos Galanis","doi":"10.46582/jsrm.1601002","DOIUrl":"https://doi.org/10.46582/jsrm.1601002","url":null,"abstract":"<p><p><b>Introduction:</b> Introduction: Knee osteoarthritis (OA) is a common pathology and is one of the leading causes of chronic disability among people aged over 65 years old. Currently, cell-based therapies involving intra-articular delivery of MSCs have emerged as a potential treatment solution. <b>Objective:</b> The purpose was to examine the current literature regarding the clinical application of adipose-derived mesenchymal stem cells (AD-MSCs) for the management of knee OA. <b>Materials and methods:</b> The electronic database, PubMed was searched from inception to May 31, 2019. This review included studies using cell population containing AD-MSCs for the treatment of knee OA. Data on clinical outcomes measured by various instrument such as VAS, WOMAC, KSS, KOOS, SF-36 were analysed, while MRI provided reliable and quantitative data on cartilage status throughout most compartments of the knee. <b>Results:</b> A total of eight studies were included. Six studies used cultured AD-MSCs, while two studies used stromal vascular fraction. There were no significant adverse events related to the procedure, while the most of studies reported improvement from baseline in at least one outcome measure. The findings were not necessarily reflected in MRI evaluations nor were improvements always maintained after 2 years follow-up. <b>Conclusion:</b> Our data suggest that the intra-articular injection of autologous AD-MSCs is a safe and effective therapeutic alternative for the treatment of severe knee OA patients and may have the potential to attenuate progression of the disease.</p>","PeriodicalId":17155,"journal":{"name":"Journal of Stem Cells & Regenerative Medicine","volume":"16 1","pages":"3-9"},"PeriodicalIF":2.7,"publicationDate":"2020-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7282271/pdf/jsrm_16_3.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38042443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Human adipose-derived stromal vascular fraction: characterization, safety and therapeutic potential in an experimental mouse model of articular injury.","authors":"Jordan A Dykstra,&nbsp;Elliot D Blue,&nbsp;Pedro L Negrão de Assis,&nbsp;Jill M Weimer,&nbsp;Daniel Jiro Kota","doi":"10.46582/jsrm.1601004","DOIUrl":"https://doi.org/10.46582/jsrm.1601004","url":null,"abstract":"<p><p>Due to their capacity to self-renew, proliferate and generate multi-lineage cells, adult-derived stem cells offer great potential in regenerative therapies to treat maladies such as diabetes, cardiac disease, neurological disorders and orthopedic injuries. Commonly derived from adipose tissue, the stromal vascular fraction (SVF), a heterogeneous cell population enriched with mesenchymal stem cells (MSCs), has garnered interest as a cellular therapy due to ease of accessibility as an autologous, point-of-care application. However, the heterogeneous cell population within SVF is not historically taken into consideration when injecting into patients. Here, we characterized SVF, determined its safety and verify its therapeutic effects in a NOD/scid mouse model of articular injury. SVF were isolated from lipoaspirates utilizing a commercially available system (InGeneron Inc.), while MSCs were isolated from SVF via cell culture. Flow cytometry showed that neither age nor BMI affects the frequency of progenitor cells-like (CD31+CD34+), immune cells-like (CD4+) T cells, (CD14+) monocytes and total number of cells obtained. However, there was a negative correlation between donor BMI and MSC frequency within the SVF. ELISAs showed that following LPS activation in SVF, there were low levels of TNF-α and high levels of IL-10 secreted. However, T cell activation with anti-CD3 or anti-CD3+ anti-CD28, while leading to expected high levels of IFN-γ, did not lead to significant levels of TGF-β. PCR analysis showed no significant numbers of cells outside the joint 1-hour post injection, moreover, no engraftment or abnormal growth in other organs 60-days post injection. Finally, both cell populations were able to ameliorate disease progression, as confirmed by the increase in movement of treated groups compared to injured groups. Noteworthy, the histological analysis indicated that there was no cartilage growth, suggesting an alternative therapeutic mechanism to cartilage regeneration.</p>","PeriodicalId":17155,"journal":{"name":"Journal of Stem Cells & Regenerative Medicine","volume":"16 1","pages":"16-25"},"PeriodicalIF":2.7,"publicationDate":"2020-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7282273/pdf/jsrm_16_16.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38042445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Custom tailoring of Cell therapies to address cartilage damages efficiently.","authors":"","doi":"10.46582/jsrm.1601001","DOIUrl":"10.46582/jsrm.1601001","url":null,"abstract":"","PeriodicalId":17155,"journal":{"name":"Journal of Stem Cells & Regenerative Medicine","volume":"16 1","pages":"1-2"},"PeriodicalIF":2.7,"publicationDate":"2020-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7282270/pdf/jsrm_16_1.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38042442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Novel function of Nebivolol: Stimulation of Adipose-derived Stem Cell Proliferation and Inhibition of Differentiation.","authors":"Dong Lin,&nbsp;Joana E Ochoa,&nbsp;Zahra Barabadi,&nbsp;Andreas B Pfnur,&nbsp;Stephen E Braun,&nbsp;Reza Izadpanah,&nbsp;Eckhard Alt","doi":"10.46582/jsrm.1601003","DOIUrl":"https://doi.org/10.46582/jsrm.1601003","url":null,"abstract":"<p><p>Tissue engineering is limited by the time of culture expansion of cells needed for scaffold seeding. Thus, a simple means of accelerated stem cell proliferation could represent a significant advance. Here, Nebivolol was investigated for its effect on the replicative capacity of adipose-derived stem cells (ASCs). This study indicates that the number of ASCs with Nebivolol treatment showed a significant population increase of 51.5% compared to untreated cells (p<0.01). Cell cycle analysis showed a significant decrease in the percentage of ASCs in G1 phase with Nebivolol treatment compared to untreated cells (p<0.01), suggesting that Nebivolol shortens the G1 phase of ASCs, resulting in a faster proliferative rate. Furthermore, our results showed that Nebivolol significantly increased colony-forming units of ASCs (p<0.01). Despite increasing ASC proliferative potential, we showed that Nebivolol has an inhibitory effect on adipogenic and osteogenic differentiation potential as indicated by significantly reduced expression of CCAAT Enhancer Binding Protein alpha (P<0.01) and lipoprotein lipase (P<0.01) and inhibited activity of alkaline phosphatase (P<0.01), respectively. Taken together, these results showed that Nebivolol accelerated ASC proliferation through shortening G1 phase, while inhibiting both adipogenic and osteogenic potentials of ASCs. These data identify a novel and simple approach to accelerate stem cell expansion <i>in vitro</i> before cell differentiation.</p>","PeriodicalId":17155,"journal":{"name":"Journal of Stem Cells & Regenerative Medicine","volume":"16 1","pages":"10-15"},"PeriodicalIF":2.7,"publicationDate":"2020-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7282272/pdf/jsrm_16_10.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38042444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Platelets using iPS cell technology; large scale manufacturing.","authors":"Koji Eto","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Induced pluripotent stem cell (iPSC) derived-platelet like particle product (iPS-platelets) is aimed to complement the current blood donor-dependent system, which is expecting the shortage of blood donors in the younger population due to the aging societies in developed countries and platelet transfusion refractoriness due to alloimmune responses. One of the strategies is to establish expandable megakaryocyte lines as a source of manufacturing cGMP grade platelets. Additionally, by scaling up of the bioreactor with novel physical parameters in optimal range, more than 100 billion iPS-platelets were produced in a 8L newly developed reactor tank towards supply of an one unit platelets concentrate (300 billion of platelets, USA). In vitro and in vivo evaluation of iPS-platelets showed the functionality comparable with donor-derived platelets. We further plan to establish the proof-of-concept of the universal HLA class-I knocked out platelets towards clinical application and the further industrial production.</p>","PeriodicalId":17155,"journal":{"name":"Journal of Stem Cells & Regenerative Medicine","volume":"15 2","pages":"52"},"PeriodicalIF":2.7,"publicationDate":"2019-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6971380/pdf/jsrm_15_52.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37581110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effects of mumie extract on cell proliferation and enzyme expression of human osteoblast-like cells (MG63).","authors":"Naser Abbasi,&nbsp;Yosra Azizpour,&nbsp;Monireh Azizi,&nbsp;Elahe Karimi,&nbsp;Ali Aidy,&nbsp;Khairollah Asadollahi","doi":"","DOIUrl":"","url":null,"abstract":"<p><p><b>Background:</b> Mumie, as an inorganic and semi-solid herbal substance, could be obtained from crevice caves and is used for bone diseases in traditional medicine. This study investigated the effects of this substance on the expression of bone alkaline phosphatase (BALP) enzyme as well as proliferation and mortality rates of MG63 human osteoblast-like cells. <b>Materials and methods:</b> The MG63 cells were cultured and the effect of 100, 200 and 300 μg/ml of mumie extract on cell viability were compared with zoledronic acid and estradiol valerate as positive controls, as well as with MG63 cells alone as the negative control group. The activity rate of the BALP enzyme was also assessed. <b>Results:</b> During 48 hours of the study period, the concentrations of 100 and 200μg/ml of mumie extract increased the proliferation rate and decreased the mortality rate of MG63 cells significantly; however, the concentration of 300μg/ml decreased the proliferation rate and increased the mortality rate of the cells. Also, BALP enzyme expression was slightly affected by 100 and 200 μg/ml of mumie extract whilst it was significantly decreased by the concentration of 300 μg/ml. <b>Conclusion:</b> This study showed that mumie extract has an increasing effect on proliferation rate and a decreasing effect on the mortality rate of osteoblast cells in low concentrations; however, the higher concentrations of this substance could be toxic and effect inversely.</p>","PeriodicalId":17155,"journal":{"name":"Journal of Stem Cells & Regenerative Medicine","volume":"15 2","pages":"18-23"},"PeriodicalIF":2.7,"publicationDate":"2019-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6971378/pdf/jsrm_15_18.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37579831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical trial in a dish; A rewarding step towards translation & perspectives on its limitations.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":17155,"journal":{"name":"Journal of Stem Cells & Regenerative Medicine","volume":"15 2","pages":"16-17"},"PeriodicalIF":2.7,"publicationDate":"2019-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6971382/pdf/jsrm_15_16.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37579830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increased mesodermal and mesendodermal populations by BMP4 treatment facilitates human iPSC line differentiation into a cardiac lineage.","authors":"Maya Kimura,&nbsp;Hatsue Furukawa,&nbsp;Masanobu Shoji,&nbsp;Tadahiro Shinozawa","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Human induced pluripotent stem cell-derived cardiomyocytes (hiPS-CMs) have attracted attention as a novel tool for drug safety screening and several differentiation protocols of hiPSC lines into cardiomyocytes have been reported; the standardization of these protocols will expand their applications for safety assessments such as \"clinical safety trial-on-dish\". Bone morphogenetic protein 4 (BMP4) is an important factor in promoting mesoderm differentiation and BMP4 treatment has been used at the early stage of cardiac differentiation into different hiPSCs. In the present study, we evaluated the effects of BMP4 treatment at the early stage of cardiac differentiation. We performed gene expression profiling of the germ layer during mesoderm differentiation of hiPSCs derived from three different donors. The expression of <i>T</i> (a mesoderm marker) and <i>GATA6</i> (an endoderm marker) increased and that of <i>PAX6</i> (a neuroectoderm marker) decreased in pooled embryoid bodies (EBs) after BMP4 treatment. Single-cell gene expression analysis revealed that mesodermal and mesendodermal populations increased in EBs derived from 253G1. Finally, BMP4 treatment increased mesodermal and mesendodermal populations compared with that without BMP4 in two other hiPSC lines, confirming the reproducibility of multiple hiPSC lines. Thus, our results suggest that BMP4 treatment increases mesodermal and mesendodermal populations at the early stage of cardiac differentiation in different hiPSC lines.</p>","PeriodicalId":17155,"journal":{"name":"Journal of Stem Cells & Regenerative Medicine","volume":"15 2","pages":"45-51"},"PeriodicalIF":2.7,"publicationDate":"2019-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6971377/pdf/jsrm_15_45.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37581111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}